Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders

Teresa H. Wen, Devin K. Binder, Iryna M. Ethell and 1 more

Frontiers in Molecular Neuroscience · 2018 · Review

doi:10.3389/fnmol.2018.00270

Abstract

Perineuronal nets (PNN) are extracellular matrix (ECM) assemblies that preferentially ensheath parvalbumin (PV) expressing interneurons. Converging evidence indicates that PV cells and PNN are impaired in a variety of neurological disorders. PNN development and maintenance is necessary for a number of processes within the CNS, including regulation of GABAergic cell function, protection of neurons from oxidative stress, and closure of developmental critical period plasticity windows. Understanding PNN functions may be essential for characterizing the mechanisms of altered cortical excitability observed in neurodegenerative and neurodevelopmental disorders. Indeed, PNN abnormalities have been observed in post-mortem brain tissues of patients with schizophrenia and Alzheimer's disease. There is impaired development of PNNs and enhanced activity of its key regulator matrix metalloproteinase-9 (MMP-9) in Fragile X Syndrome, a common genetic cause of autism. MMP-9, a protease that cleaves ECM, is differentially regulated in a number of these disorders. Despite this, few studies have addressed the interactions between PNN expression, MMP-9 activity and neuronal excitability. In this review, we highlight the current evidence for PNN abnormalities in CNS disorders associated with altered network function and MMP-9 levels, emphasizing the need for future work targeting PNNs in pathophysiology and therapeutic treatment of neurological disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

First described by Golgi and Cajal, PNNs are assemblies of ECM proteins, which form net-like structures around neurons. While PNNs were first identified in the late 1800s, much of our current knowledge about PNN structure and function can be attributed to a renewed interest in PNNs almost a century later. Since then, PNNs have been implicated in a wide range of functions including neuroprotection, regulation of neural activity and experience-dependent plasticity. Excellent reviews have been written about the role of PNNs in brain development. Recently, increasing evidence suggests that PNNs are altered in various neurodevelopmental and neurodegenerative disorders associated with changes in brain activity. In parallel, a number of these CNS diseases exhibit dysregulated expression of enzymes necessary for PNN cleavage and reorganization. However, the role of PNNs in neural and network excitability is only beginning to be understood. Based on evidence from recent studies in the mouse model of FXS, we propose a novel working hypothesis in which MMP-9 mediated cleavage and/or reorganization of PNN structures around PV-expressing cells contributes to abnormal PV cell development and cortical hyperexcitability (Figure 1). Using this hypothesis as a scaffold, we bring together evidence from studies of schizophrenia, AD, and epilepsy to suggest that systematic studies of the interplay between MMP-9, PNN and PV cells may be key to understanding mechanisms of multiple CNS disorders at the cellular and circuit levels.

PNN Structure and Developmental Regulation of its Components

Perineuronal nets are specialized assemblies of ECM proteins which ensheath neurons and proximal dendrites. PNNs are composed of CSPGs, tenascin, and link proteins, which facilitate binding to a hyaluronan backbone (Figure 2). Developmental regulation of ECM proteins, which make up PNNs, may underlie PNN formation, composition, and function. The developmental changes in major PNN proteins are discussed in the following sections:

Chondroitin Sulfate Proteoglycans

Chondroitin sulfate proteoglycans consist of a core protein and varying amounts of chondroitin sulfate chains covalently bound to a central region of the protein. These chondroitin sulfate side chains are a type of GAG polysaccharide consisting of disaccharide blocks of N-acetylgalactosamine and glucuronic acid. Various CSPGs exist in the ECM throughout the body, but the lectican family of CSPGs is most prominent in PNNs of the CNS. These include aggrecan, neurocan, versican, and brevican, which vary in core protein size and the number of GAG side chains.

Although lecticans are developmentally regulated, their function in CNS development remains unclear. A developmental upregulation of aggrecan and brevican, which peak in adulthood, was reported in rat brain. Versican consists of two different alpha and beta isoforms, which are differentially expressed during development. The expression of alpha isoform was low during embryonic development, first and second postnatal weeks, and then increased steadily until around 3.5 months of age. In contrast, the expression of beta isoform increased 2–3 fold from embryonic day (E) 14 until birth and then decreased in adulthood. Neurocan expression also increased between E14 and postnatal day (P) 3 and then decreased during early-late adolescence and into adulthood. Studies of postmortem human tissues also suggest developmental changes in lectican levels in human CNS. For example, high levels of brevican mRNA expression were detected in postmortem human cortex during early development until 8 years of age, and the expression levels were lower in the adult human brain. These developmental changes in lectican expression levels suggest that the PNNs themselves may also be developmentally regulated, underlying maturation of circuit function. However, the functional impact of developmental changes in PNN lectican composition is unknown.

Tenascins and Hyaluronan

Tenascins and hyaluronan are also part of PNN structure. Tenascins are fibrous, matricellular proteins, which bind to the C-terminal domain of lecticans. Hyaluronan is an unsulfated GAG that is synthesized at the cell surface by the membrane-bound enzymes called HAS and protrudes through the plasma membrane into the extracellular space. Hyaluronan binds to other ECM molecules via N-terminal hyaluronan binding domains, including lecticans and link proteins such as cartilage link protein, Ctrl1, and brain-derived link proteins Bral1 and Bral2. This complex of hyaluronan with ECM proteins forms the basis for PNN structure. Similar to lecticans, tenascin and hyaluronan are also developmentally regulated. In the mouse cortex, tenascin immunolabeling is first detected around E16 and tenascin levels increase after birth until the third postnatal week. By week 4, tenascin expression is reduced to adult levels. Hyaluronan expression precedes the detection of both tenascin and lecticans, and is first observed near the notochord in E11-12 rat embryos. Hyaluronan is expressed during postnatal development and adulthood but peaks during embryonic development.

While lecticans, tenascins, and hyaluronan are expressed during embryonic development, the classic net-like structure of PNNs is not typically seen until later during postnatal development. It is unclear how these molecules are assembled to form PNN around neurons, but some studies suggest that both neurons and glial cells are involved in the process. Astrocytes extend their processes into PNNs localized near the synapse, suggesting a tetrapartite synaptic organization involving ECM, pre/post synaptic sites and astrocytes whose synergistic functions remain unexplored.

Parvalbumin Expressing Interneurons, PNNs and MMP-9

In the forebrain, PNNs are often found on PV expressing GABAergic neurons (Table 1). Other cell types, including putative excitatory neurons also contain PNNs but they are less numerous compared to GABAergic-PNN expressing cells. Most studies detecting PNNs in the CNS use fluorescently coupled lectins, such as WFA and vicia villosa agglutinin, which bind N-acetylgalactosamine on chondroitin sulfate GAG side-chains of CSPGs. Immunolabeling using antibodies against specific PNN proteins, including aggrecan, tenascin and hyaluronan can also be used to visualize PNNs. Studies comparing PNNs detected with lectins or specific antibodies indicate substantial levels of molecular heterogeneity, highlighting the need for better approaches which address PNN heterogeneity. In the following discussion, most studies use lectin based detection of PNNs unless noted otherwise.

Parvalbumin cells are a major class of GABAergic, fast-spiking inhibitory interneurons in the neocortex. Cortical PV cells contribute to synchronous oscillatory activity, particularly in the gamma range (∼30–100 Hz). Like PNNs, PV expression is developmentally regulated and experience-dependent. In fact, PV and PNN colocalization is correlated with critical period closure and reduced synaptic plasticity, particularly in sensory cortices. A large proportion of PNN-expressing PV cells is found within layer 4 of neocortex (Table 1). Interestingly, developing auditory cortex appears to exhibit fewer PNN and PV expressing cells than visual or somatosensory cortex, but in adult sensory cortices, a majority of PV cells express PNNs as seen with WFA staining. PNNs may regulate PV cell functions, as PNN reorganization is shown to result in abnormal CNS development and altered neural excitability.

MMP-9 is a zinc-dependent endopeptidase expressed in various cells within the CNS which is capable of cleaving ECM proteins, including collagen and laminin (reviewed in ). Peak MMP-9 expression is observed during postnatal development and is reduced during adulthood. High levels of MMP-9 contribute to proteolytic cleavage of ECM, creating an extracellular environment that is permissive for synaptic plasticity. As aggrecan has been previously identified as an MMP-9 target, aggrecan-rich PNNs may be unstable in the presence of MMP-9, leading to abnormal development and neural excitability. A recent study by Murase and colleagues demonstrated that PV, PNN, and MMP-9 interactions are important for driving adult plasticity. In this study, monocular deprivation followed by light exposure in adult mice was associated with reduced WFA-expressing PNNs, lower aggrecan levels, and increased MMP-9 activity, as well as reduced PV cell output, increased firing of regular-spiking cells, and reduced gamma power. These findings suggest a link between PNNs, MMP-9 activity and PV activity that shapes normal brain development. Conversely, abnormal interactions may lead to neurological disorders.

Fragile X Syndrome

Recently, we proposed a hypothesis for increased sensory hyperexcitability in Fragile X syndrome (FXS) through increased MMP-9 levels and abnormal PNN development (Figure 1). FXS is a leading genetic cause of autism, occurring in 1 in 4000 males and 1 in 8000 females. The most common cause of FXS is an expansion of CGG trinucleotide repeats in 5′ region of the Fragile X mental retardation 1 (Fmr1) gene that results in its hypermethylation and inactivation. This leads to loss of Fragile X Mental Retardation protein (FMRP), which is necessary for regulation of protein synthesis. Individuals with this neurodevelopmental disorder suffer from social and communication deficits, sensory hypersensitivity, and anxiety disorders. Auditory hypersensitivity is common in humans with FXS as measured by increased sound evoked responses, reduced habituation and expansion of brain regions activated by auditory stimuli. These auditory processing deficits may drive social, cognitive and language delays and deficits in FXS.

Auditory hypersensitivity is also evident in Fmr1 knockout (KO) mice, a mouse model of FXS, which exhibit increased susceptibility to audiogenic seizures and abnormal auditory startle. In vivo electrophysiological studies demonstrate that neurons in adult Fmr1 KO mouse auditory cortex (1) are hyperexcitable, exhibiting increased responses per stimulus, (2) show more variable response latencies, and (3) display broader frequency tuning curves. Recent work using EEG/ERP recordings shows that mature Fmr1 KO mouse auditory cortex exhibits reduced habituation to repeated sound presentations. When resting EEG is analyzed for spectral power distribution, Fmr1 KO mouse cortex shows increased gamma power. There is also enhanced N1 amplitude and reduced gamma phase locking in auditory ERPs. These phenotypes in the mouse model are remarkably similar to those seen in humans with FXS. These results indicate that there is altered E/I balance in auditory cortex, which may underlie auditory hypersensitivity phenotypes. As PNNs are thought to be critical for maintaining E/I balance by modulating PV neuron activity, we tested the hypothesis that disruption of PNN development may underlie auditory hypersensitivity in FXS.

We found delayed PNN development and increased MMP-9 activity levels in the developing auditory cortex of Fmr1 KO mice, which may lead to impaired PV cell development and reduced inhibition. These phenotypes were mostly observed between P14 and P21 suggesting a window of abnormal development that can be targeted for therapeutic applications. At P14, the responses of single neurons were similar across genotypes, while at P21, Fmr1 KO neurons show hyper-responsiveness. Genetic reduction of MMP-9 levels in the Fmr1 KO mice normalized PV/PNN development and also reversed the hyperresponsiveness of auditory cortical neurons. These findings suggest that MMP-9-mediated cleavage of PNNs during development may underlie sensory hypersensitivity in FXS. Reduction of MMP-9 levels with minocycline in humans with FXS contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS. Minocycline administration in Fmr1 KO mice prevents abnormal dendritic spine development in the hippocampus, improves anxiety-like behaviors and corrects ultrasonic vocalizations. Genetic reduction of MMP-9 in Fmr1 KO mice normalizes PNN formation and prevents the development of neuronal hyperexcitability, emphasizing the therapeutic potential of targeting MMP-9 and PNN in treatment of FXS.

In addition to regulating cortical development, MMP-9 cleavage of PNNs may drive changes in PV expression and/or PV cell functions seen in FXS. The somatosensory cortex of adult FXS mice exhibit delayed PV cell maturation. In developing mice, PV interneurons receive reduced excitatory drive from neighboring pyramidal cells in layer 4 of somatosensory cortex. PV cell maturation is characterized by gradual increases in signaling, including faster firing rates and IPSC kinetics. An orthodenticle homeoprotein, Otx2, may play a role in PV cell maturation and refinement of cortical inhibition. Otx2 expression coincides with both PV and PNN expression in the cortex during critical period plasticity. Studies of rodent visual cortex development indicate that Otx2 is localized to GABAergic cells, and is more likely found in PV cells that are enwrapped with PNNs, which contain a specific Otx2 binding site. PNNs are necessary for the uptake of Otx2 by PV cells, which promotes PV cell maturation. RNA sequencing analysis of PV cells containing Otx2 indicates that Otx2 may be necessary for mitochondrial function, cellular respiration, and redox regulation. These data suggest that PNNs may drive PV cell maturation by directing transcription or translation of specific genes necessary for PV cell function. In FXS, delayed PNN expression around PV cells during development may contribute to abnormal PV cell maturation.

Network excitability in FXS may also result from impaired synaptic scaling at PV cells due to PNN dysfunction. There is evidence for a role of PNNs in mediating synaptic scaling via neuronal activity-regulated pentraxin, also known as Narp. Narp can interact with the N-terminal domain of AMPA receptors localized extracellularly and facilitate AMPA receptor clustering at both the pre- and post-synaptic cell in response to stimulation. Studies by in developing mouse hippocampus demonstrated that (1) Narp was highly expressed at excitatory synapses on PV interneurons, (2) PNN expression facilitated Narp expression (and conversely PNN degradation contributed to reduced Narp levels), and (3) Narp expression at PV interneurons was necessary for increased AMPA receptor-mediated mEPSC amplitude in response to stimulation both in vitro and in vivo. This suggests that during development, sensory stimuli can activate Narp expression which promotes PV interneuron excitation, leading to feed-forward inhibition. In FXS, delayed development of PNNs may contribute to abnormal Narp expression, impairing the ability of PV cells to scale cortical networks, resulting in cortical hyperexcitability.

Schizophrenia

One mechanism that has been proposed to explain some symptoms of schizophrenia is a reduction in GABAergic signaling in specific cortical regions. This is evident from a number of studies characterizing GABAergic cells using antibodies which target GABA-synthesizing enzymes glutamate decarboxylase 65 and 67 (GAD65 and GAD67) in brain tissues from schizophrenia patients. In situ hybridization and RT-PCR studies indicate that post-mortem brain tissues from schizophrenia patients exhibit reduced PV and/or GAD67 mRNA, particularly in prefrontal cortex. Reduced PV and GAD67 protein levels are also seen in both prefrontal and temporal cortex of post-mortem brain tissues. Cortical gamma band oscillations have been attributed to GABAergic cell activity, in particular PV interneurons. Increased gamma-band power was observed in baseline EEG recordings from humans with schizophrenia. In contrast, gamma-band activity that is driven by rapid presentation of auditory stimuli and synchrony or phase-locking of electrocortical activity to these stimuli are reduced in schizophrenic patients compared to healthy controls. These data suggest altered PV cell function in schizophrenia, but why these cells are susceptible is unclear.

Redox dysregulation has been observed in schizophrenic patients, who have defective antioxidant systems and exhibit increased lipid peroxidation. Genetic analysis of single nucleotide polymorphisms in schizophrenia patients demonstrates mutations in the gene encoding GCL, an enzyme that is important for the production of the cellular antioxidant GSH. PV cells are particularly susceptible to oxidative stress given their fast cellular metabolism and increased mitochondrial function. Recent studies show that PNNs may protect PV cells from oxidative stress, and thus serve as a ‘safety net’ to support the rapid firing properties of PV cells. Cabungcal and colleagues analyzed the levels of oxidative stress in PV cells with and without PNNs in GCL KO mice, a mouse model of schizophrenia, by measuring the levels of 8-hydroxy 2 deoxyguanosine (8-oxo-dG). During development, GCL KO mice had fewer PNN-expressing PV cells in anterior cingulate cortex, and the injection of a dopamine reuptake inhibitor to promote more oxidative stress via buildup of reactive oxygen species contributed to increased 8-oxo-dG signal and PV cell loss. Further analysis indicated that while PV neurons with PNNs were less susceptible to oxidative stress, chABC-mediated degradation of PNNs made PV cells more vulnerable. As chABC removes GAG side chains from CSPGs, these results suggest that the neuroprotective effects of PNNs may be attributed to the CS-side chains of CSPGs. Specifically, in vitro studies conducted in human neuroblastoma SH-SY5Y cells indicate that chondroitin sulfate application prior to exposure to oxidative-stress inducing agents, such as hydrogen peroxide, can prevent cell death and attenuate the production of reactive oxygen species. Analysis of molecular mechanisms indicates that chondroitin sulfate promotes activation of protein kinase pathways including PKC and PI3K/Akt, and subsequent production of a neuronal antioxidant, heme oxygenase-1.

Perineuronal net dysfunction in schizophrenia may also drive changes in GABAergic cell function leading to network dysfunction, as normal PNN expression regulates excitability of PV cells. speculated that the large, negatively charged sugar chains, which are enriched in PNNs, might allow for buffering of sodium and potassium ions at synapses. While this mechanism has not been confirmed, chABC-mediated removal of chondroitin sulfate side chains from PNNs reduced spiking of PV cells in adult rats and increased spiking variability. In addition, brevican conditional knockdown in PV-expressing cells demonstrated that changes in the expression of specific lecticans alter synaptic input and firing frequency in PV cells. These findings lend support to the idea that PNN composition plays an important role in regulating PV cell function.

As PNNs regulate GABAergic cell function and oxidative stress levels, cortical abnormalities observed in schizophrenia may be attributed to PNN dysfunction (reviewed in; ). Indeed, several studies indicate that schizophrenia is associated with the loss of PNNs. Post-mortem brains from patients with schizophrenia exhibit reduced density of WFA-labeled cells and reduced levels of CSPGs and PV expression in prefrontal cortex. A mouse model of schizophrenia also exhibits reduced PNN levels in prefrontal cortex. In this model, schizophrenia-like abnormalities are reported in the adult mouse prefrontal cortex as a result of neonatal lesion of ventral hippocampus. The effects of dysregulated dopamine signaling on prefrontal cortex oscillatory activity, which are suggested to drive schizophrenia phenotypes, can be also regulated by PNNs. For example, network oscillatory activity that was increased by drug-induced changes in dopaminergic signaling in mouse prefrontal cortex was further enhanced following chABC-mediated degradation of PNNs.

Recent studies have hinted at the potential role of MMP-9 in the manifestation of schizophrenia phenotypes. A functional polymorphism of the MMP-9 gene was discovered in human schizophrenia patients. Additionally, showed elevated MMP-9 levels in the plasma of schizophrenic patients. Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning. Beside its antibiotic activity, minocycline can reduce plasma levels of MMP-9 and inhibit MMP-9 activity, suggesting a possible role of MMP-9 inhibition in the beneficial effects of minocycline in schizophrenia. Clearly additional studies are needed to test whether elevated MMP-9 levels do indeed drive PNN changes observed in prefrontal cortex of schizophrenia mouse models and how it relates to the human condition. Future studies can help to determine whether ECM abnormalities underlie the changes in GABAergic signaling and redox dysregulation associated with schizophrenia.

Seizures and Epilepsy

Epilepsy occurs unpredictably and affects people of all ages, although onset commonly occurs in childhood. It is idiopathic and can include generalized seizures, which involve epileptiform activity emanating from the entire cortex, as well as focal or partial seizures, which result from epileptiform activity from a single part of the cortex. The molecular mechanisms underlying seizure onset include impaired PV cell functions. Analysis of post-mortem human brain tissues demonstrated reduced PV cell density and immunoreactivity at epileptic foci in the hippocampus and neocortex. Genomic sequencing data indicate that a number of mutations in the Scn1a gene contribute to a spectrum of different epileptic disorders affecting children, including de novo as well as missense, frame-shift, and nonsense mutations. Scn1a is a gene that encodes Nav1.1, a sodium channel necessary for PV cell firing. Recent studies demonstrate that reduced PV cell spike output may contribute to seizures in mice with genetic knock-in of mutated human Scn1a, which results in subtle changes in Nav1.1 functionality. Several rodent models of epilepsy, which use drugs to induce seizures, also shed some light on the role of PV cells. For example, PV KO mice are more likely to experience status epilepticus compared to controls following increased doses of pentylenetetrazol (PTZ), a GABAA receptor blocker.

As PNNs regulate PV cell activity and protect PV cells from oxidative stress, PNNs can be potentially targeted to control seizures. Recent work has reported changes in PNN integrity in epilepsy. Drug-induced seizures led to increased expression of aggrecan cleavage products around PV cells and reduced expression of PNN components in rodent hippocampus, including Ctrl1 and hyaluronan synthase 3, both of which help to stabilize PNNs. Drug-induced seizures increased unbound CSPG levels and decreased the levels of CSPGs associated with PNNs around PV cells, which were detected with WFA in cerebral cortex. In rodent piriform cortex, kindling-induced seizures caused PNN degradation and increased GABAergic synapses, contributing to the rewiring of cortical networks. Moreover, PNN breakdown induced by seizures was at least partially facilitated by increased enzymatic activity of MMPs, and seizure susceptibility was reduced in MMP-9 KO mice. This suggests that PNN breakdown via MMP-9 following seizure induction contributes to network rewiring, leading to pathological hyperexcitability. Future studies should explore this PNN loss-hyperexcitability connection further and determine whether there would be therapeutic benefit to MMP inhibition and PNN restoration in epilepsy.

CNS Injury and Stroke

In CNS injury and stroke, re-establishing neuronal plasticity appears to be key for re-innervation and recovery. A full summary of this literature is outside the scope this review, so only a few exemplars are mentioned to make the point that understanding the contributions of PNN and other ECM molecules may be critical in developing treatments, because the CSPGs present in PNNs appear to inhibit axonal growth. In rat spinal cord injury models, increased concentrations of CSPGs and PNN expression were found at injury sites and surrounding secondary dorsal column relay neurons. When sensory axons were transplanted into adult rats with dorsal column lesions, neurons were able to sprout and extend their processes to additional denervated areas, but failed to penetrate the original lesion sites, which lead to denervation of upstream pathways and inactivation of parts of somatosensory cortex. CSPG degradation via application of chABC promoted regeneration of dorsal column axons after injury. This not only resulted in an increase in terminals from initially injured afferents, but also contributed to expanded receptive fields of uninjured primary afferents.

Studies in stroke models indicate that injury onset leads to two processes. On the one hand, focal cortical stroke in rats contributes to upregulation of a number of CSPG-encoding genes particularly near the infarct and glial scar. RT-PCR analysis of the affected tissue indicated upregulation of neurocan, which peaked on the third day following middle cerebral artery occlusion, as well as versican and brevican, both of which peaked by day 28. In contrast, in cortical areas surrounding the infarct and outside of the glial scar, WFA-expressing PNNs are completely degraded by day 7, and CSPG immunoreactivity is down regulated although they remain detectable up to 14 days post-injury. Similar degradation of WFA-expressing PNNs in the neocortex has also been observed following thromboembolic middle cerebral artery occlusion in rats, permanent middle artery occlusion in mice, and focal cerebral ischemia in sheep. Interestingly, reduced PV-immunoreactivity and PV cell function have also been observed following stroke and this decrease in inhibitory cell function may underlie epilepsy-like activity following stroke. As CSPGs inhibit growth, these findings indicate that spinal cord injury, stroke and/or traumatic brain injury may contribute to ECM reorganization, allowing neuronal growth and plasticity in areas free from damage and inhibiting growth where injury-induced cellular damage is more severe. MMP-9 may be responsible for this ECM reorganization as a number of studies have demonstrated increased MMP-9 levels following CNS injury and stroke in humans as well as animal models.

Alzheimer’S Disease

Alzheimer’s disease is associated with memory impairment, which may be attributed to intracellular buildup of neurofibrillary tangles and the accumulation of extracellular beta-amyloid plaques in hippocampus and cortex. This may lead to hippocampal and cortical hyperexcitability as well as increased seizure susceptibility in both AD humans and rodent models. Post-mortem brains of AD patients exhibit reduced expression of PNNs, particularly in the hippocampus. Neurons that exhibit buildup of tau protein and neurofibrillary tangles are more likely to lack PNNs. Direct support for the neuroprotective effects of PNNs from AD-related pathology was demonstrated in rodent cortical neurons in vitro. These experiments showed that PNN-ensheathed cells were more resistant to cell death when neurons were incubated with exogenous monomeric Aβ1-42 peptide for 48 h. More cells died when pretreated with chABC. The neuroprotective abilities of PNNs may stem from their ability to act as a barrier for oxidative stress-inducing molecules, such as metal ions. The molecules can react with free radicals generated by cellular metabolism to generate even more free radicals, resulting in lipid peroxidation, oxidative stress, and cell death. Indeed, cortical cells expressing PNNs exhibited accumulation of iron in post-fixed brain tissues obtained from both AD and normally aged controls. Accumulation of lipofuscin, a byproduct of iron-catalyzed oxidative stress, was also observed in cells without PNN. These results indicate that cells without PNNs are more susceptible to cell death. Similar results have been obtained in AD rodent models, which rely on bilateral or unilateral microinjection of iron chloride into mouse cortex to mimic AD-related oxidative stress. While iron-induced oxidative stress resulted in apoptotic cell death in cells without PNNs, neurons with PNNs were more likely to survive. Genetic reduction of aggrecan, which has the highest number of CS-side chains and presumably the largest negative charge, resulted in reduced neuroprotective effects. These results lend further support to the idea that the CS-side chains of PNNs mediate its neuroprotective effects.

Perineuronal net loss in AD may contribute to altered E/I balance, synaptic loss and increased susceptibility to oxidative stress. Interestingly, some studies suggest that MMP-9 may be a key molecular target in treating AD, as MMP-9 is capable of cleaving Aβ in vitro, and plasma levels of MMP-9 are elevated in AD patients. As MMP-9 is also involved in PNN maintenance, elevated MMP-9 levels may contribute to both PNN degradation and altered levels of Aβ in AD.

Hearing Loss and Central Auditory Processing

Recent studies suggest that loss of PNNs around PV cells occurs following noise-induced and age-related hearing loss. Overexposure to loud sounds can cause hair cell damage, hearing loss and reduced afferent input in the auditory system. Noise-induced hearing loss leads to increased excitability (gain) in the central auditory system, but the cellular mechanisms are not clear. PNNs are impaired following noise induced hearing loss, even within 1 day after noise exposure. Specifically, PNN intensity is reduced in layers 1–4 of auditory cortex of adult CBA mice 1, 10, and 30 days post-noise exposure. In layers 5–6, PNN intensity decreases 10 days post-noise exposure. Reduced PNN intensity may be a result of increased cleavage or degradation of various PNN components, such as CSPGs, hyaluronan, or link proteins. In brainstem auditory nuclei of mice, genetic loss of brevican contributes to loss of brevican-expressing PNNs as well as reduced sound-evoked firing rates and increased neuronal response thresholds. chABC-mediated degradation of PNNs around PV cells in brainstem and central auditory neurons has similar effects, resulting in reduced PV cell excitability and gain. These results indicate that PNNs may be necessary for neuronal excitability throughout the auditory pathway. Understanding the auditory system’s ability to control excitability as a result of exposure to traumatic sounds and the potential role of PNNs in regulating this process may help to characterize molecular targets in treatment of noise induced hearing loss and tinnitus.

Age-related hearing loss, also known as presbycusis, is associated with difficulty interpreting speech and slower auditory processing which may lead to social isolation and cognitive decline. Hearing aids amplify sounds, but may not improve speech processing, suggesting central auditory system changes. Neuronal response properties susceptible to presbycusis include frequency selectivity, spontaneous activity levels and spectrotemporal selectivity. GABAergic signaling is involved in shaping these properties, with fast-spiking PV cells shaping both spectral and temporal selectivity. Indeed, several studies have demonstrated reduced GABAergic signaling in the aged auditory system of rodents and humans.

Perineuronal nets may play a major role in PV neuron susceptibility and altered cortical processing in presbycusis. The number of PNN expressing cells is reduced in aging mouse auditory cortex with a particular impact on PV/PNN co-localized cells. As PNNs protect PV cells from oxidative stress, these data indicate that PNN downregulation with age may make PV cells more susceptible to cell death. Altered PNN formation may contribute to abnormal GABAergic signaling and impaired temporal processing with age, leading to deficits in speech comprehension. Additional studies are required to identify the specific components of PNNs that are altered in noise- and age-related hearing loss.

Conclusion and Future Studies

Accumulating evidence suggests that PNN loss is associated with a number of neurological disorders. PNNs are also implicated in experience-dependent plasticity during development. In fact, activity-dependent synaptogenesis and the development of stable neuronal networks may be a result of normal PNN interactions with inhibitory interneurons, in particular fast spiking PV cells. Despite the evidence for developmental and pathological changes in PNNs, their precise role in network function and development is not known. Additional studies are needed that compare intrinsic and synaptic properties of the same cell types with and without PNNs. While the use of chABC has been useful in addressing PNN function, this enzyme likely has broader effects. Additional methods such as genetic removal of specific PNN components are needed.

Considering the prominent role of PNNs in many processes within the CNS, more focus should be placed on characterizing the mechanisms of PNN regulation in the healthy and diseased brain. Some of the work reviewed here indicates that PNNs are necessary for PV cell function, yet in several brain areas not all PV cells are ensheathed by PNNs as labeled with WFA (Table 1). PNNs are heterogeneous structures, and PNN composition may be brain region- and developmental age-specific. For instance, in the rodent hippocampus, aggrecan-expressing PNNs overlap with WFA labeling in stratum oriens, but stratum pyramidale exhibits aggrecan-rich PNNs, which are not WFA-positive. PNNs containing aggrecan and brevican do not always overlap in mouse somatosensory cortex. Tenascin-R expressing PNNs are not observed in rodent PFC, but are prominent in other cortical areas. These findings suggest that future work characterizing other PNN components such as hyaluronan will be helpful in understanding PNN development and re-organization in health and disease. New models that allow for the examination of PNN formation and restructuring in the living brain will contribute to a better understanding of its role in circuit function. Genetic approaches to visualize and disassemble PNNs will also be very important moving forward.

Mechanisms of PNN loss and restructuring in disease are still not clear. One of the ECM modifying enzymes, MMP-9, has been hypothesized to play a role in pathophysiology of schizophrenia, AD and FXS. As MMP-9 is capable of cleaving ECM, elevated MMP-9 levels can drive PNN loss and re-organization. As there is evidence for abnormal MMP-9 regulation in FXS, schizophrenia and AD as well as altered PNNs in presbycusis and acoustic trauma models, studies of how MMP-9 is involved in PNN regulation are crucial for the development and validation of future therapeutics. Recent studies indicate that minocycline administration may reverse both schizophrenia and FXS phenotypes, perhaps due to its ability to lower MMP-9 levels or activity. As MMP-9 cleaves PNN components, perhaps the use of more specific MMP-9 inhibitors may yield higher efficacy in treatment of these and other neurological disorders.

While we have focused on the potential role of MMP-9 in regulating PNNs and neural excitability in disease pathology, the ADAMTs family of aggrecanases may also cause PNN cleavage and reorganization. Indeed, several ADAMTs are upregulated following spinal cord injury, stroke, and epilepsy. In addition, a number of molecules can regulate MMP-9 activity itself, including tissue inhibitors of MMPs, known as TIMPs, which form 1:1 complexes with MMPs in order to inhibit MMP activity. TIMP levels are increased in postmortem brains of AD patients, and may be indicators for risk of stroke mortality. Schizophrenia is associated with higher MMP-9/TIMP1 ratios compared to healthy controls. Future work characterizing the expression of other MMPs in disease pathology may also be useful as a number of MMPs can directly or indirectly activate MMP-9, including MMP-7, MMP-3, and MMP-14. Quantitative PCR analysis indicates that transcripts from MMP-9, 3, 7, and 14 are upregulated in rodent models of spinal cord injury. Understanding how other MMP-9 and PNN modifying enzymes are regulated may contribute to the development of new targets in treating neurological disorders.

As PNNs may play a major role in disease pathology, the development of therapeutic interventions, which target these structures, may be key in restoring neuronal excitability and cortical function. For instance, recent findings in rodent stroke models indicate that rats housed in enriched environments following ischemic damage exhibited faster neurological recovery compared to rats placed in standard housing. Quatrromani and colleagues suggest that this phenomenon may be attributed to sensorimotor stimulation which results in increased protease activity and reduced expression of PNNs. As the absence of PNNs is associated with increased plasticity, this may allow for axonal outgrowth and synaptogenesis, particularly in surviving cortical areas, which exhibit reduced CSPG and PNN expression and are therefore growth permissive (2014). These findings suggest that comparable human treatments, which target PNNs specifically, might involve non-invasive brain stimulation or combination brain stimulation/protease inhibitor treatments. While brain stimulation techniques are already currently utilized to treat neurological disorders, understanding how PNNs are modified following stimulation in rodents would lend support for use of this treatment paradigm, particularly in disorders involving abnormal PNNs.

While we do not emphasize inflammatory response pathways in the present review, these may be crucial in understanding MMP-9 dysregulation in CNS disorders as there is evidence for neuro-inflammation in injury models, AD, epilepsy, and schizophrenia. Cirillo and colleagues suggest that following insult, reactive gliosis triggers activation of MMPs and maladaptive plasticity, perhaps due to increased degradation of neurotrophins such as NGF. Neurotrophins are necessary for neuronal growth and plasticity, and increased MMP-9 activity has been shown to degrade mature NGF. Moreover, recent work in peripheral nerve injury models indicates that co-treatment with MMP-9 inhibitors and NGF peptide following insult can restore synaptic homeostasis, i.e., normalize glutamate/GABA ratio and expression of glial amino acid transporters. Unlike FXS, where MMP-9 upregulation can likely be attributed to loss of the Fmr1 gene, these findings provide important mechanistic insight for how MMP-9 dysregulation might arise in other CNS diseases. Whether NGF downregulation alters PNN expression remains to be studied. However, if NGF does play a role, this has important implications for the development of new PNN-targeting therapies.

Author Contributions

TW reviewed the literature and wrote the manuscript. IE, DB, and KR were involved in writing and editing the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer GC and handling Editor declared their shared affiliation.

References 214

  1. 1.

    Abbeduto L. Hagerman R. (1997 ). Language and communication in fragile X syndrome. Dev. Disabil. Res. Rev. 3 313–322.

    Not in our library10.1002/(sici)1098-2779(1997)3:4<313::aid-mrdd6>3.0.co;2-o

  2. 2.

    Akbarian S. Kim J. J. Potkin S. G. Hagman J. O. Tafazzoli A. Bunney W. E. Jr. (1995 ). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52 258–266.

    Not in our library10.1001/archpsyc.1995.03950160008002

  3. 3.

    Andrioli A. Alonso-Nanclares L. Arellano J. I. DeFelipe J. (2007 ). Quantitative analysis of parvalbumin-immunoreactive cells in the human epileptic hippocampus. Neuroscience. 149 131–143.

    Not in our library10.1016/j.neuroscience.2007.07.029

  4. 4.

    Aspberg A. Miura R. Bourdoulous S. Shimonaka M. Heinegård D. Schachner M. (1997 ). The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein– protein interactions independent of carbohydrate moiety. Proc. Natl. Acad. Sci. U.S.A. 94 10116–10121.

    Not in our library10.1073/pnas.94.19.10116

  5. 5.

    Backstrom J. R. Lim G. P. Cullen M. J. Tökés Z. A. (1996 ). Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1–40). J. Neurosci. 16 7910–7919.

    Not in our library10.1523/jneurosci.16-24-07910.1996

  6. 6.

    Baig S. Wilcock G. K. Love S. (2005 ). Loss of perineuronal net N-acetylgalactosamine in Alzheimer’s Disease. Acta Neuropathol. 110 393–401.

    Not in our library10.1007/s00401-005-1060-2

  7. 7.
    Perineuronal Nets Enhance the Excitability of Fast-Spiking Neurons · 2016
    No notice
  8. 8.

    Beasley C. L. Reynolds G. P. (1997 ). Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24 349–355.

    Not in our library10.1016/s0920-9964(96)00122-3

  9. 9.

    Bednarek N. Clément Y. Lelièvre V. Olivier P. Loron G. Garnotel R. (2009 ). Ontogeny of MMPs and TIMPs in the murine neocortex. Pediatr. Res. 65 296–300.

    Not in our library10.1203/pdr.0b013e3181973aee

  10. 10.

    Berardi N. Pizzorusso T. Maffei L. (2004 ). Extracellular matrix and visual cortical plasticity: freeing the synapse. Neuron 44 905–908.

    Not in our library10.1016/j.neuron.2004.12.008

  11. 11.

    Bernard C. Prochiantz A. (2016 ). Otx2-PNN interaction to regulate cortical plasticity. Neural Plast. 2016:7931693.

    Not in our library10.1155/2016/7931693

  12. 12.

    Berretta S. (2012 ). Extracellular matrix abnormalities in schizophrenia. Neuropharmacology 62 1584–1597.

    Not in our library10.1016/j.neuropharm.2011.08.010

  13. 13.

    Berretta S. Pantazopoulos H. Markota M. Brown C. Batzianouli E. T. (2015 ). Losing the sugar coating: potential impact of perineuronal net abnormalities on interneurons in schizophrenia. Schizophr. Res. 167 18–27.

    Not in our library10.1016/j.schres.2014.12.040

  14. 14.

    Beurdeley M. Spatazza J. Lee H. H. Sugiyama S. Bernard C. Di Nardo A. A. (2012 ). Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex. J. Neurosci. 32 9429–9437.

    Not in our library10.1523/jneurosci.0394-12.2012

  15. 15.

    Bignami A. Hosley M. Dahl D. (1993a ). Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix. Anat. Embryol. 188 419–433.

    Not in our library10.1007/bf00190136

  16. 16.

    Bignami A. Perides G. Rahemtulla F. (1993b ). Versican, a hyaluronate-binding proteoglycan of embryonal precartilaginous mesenchyma, is mainly expressed postnatally in rat brain. J. Neurosci. Res. 34 97–106.

    Not in our library10.1002/jnr.490340110

  17. 17.

    Bilousova T. V. Dansie L. Ngo M. Aye J. Charles J. R. Ethell D. W. (2009 ). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46 94–102.

    Not in our library10.1136/jmg.2008.061796

  18. 18.

    Blosa M. Sonntag M. Jäger C. Weigel S. Seeger J. Frischknecht R. (2015 ). The extracellular matrix molecule brevican is an integral component of the machinery mediating fast synaptic transmission at the calyx of Held. J. Physiol. 593 4341–4360.

    Not in our library10.1113/jp270849

  19. 19.

    Blümcke I. Eggli P. Celio M. R. (1995 ). Relationship between astrocytic processes and “perineuronal nets” in rat neocortex. Glia 15 131–140.

    Not in our library10.1002/glia.440150205

  20. 20.

    Bradbury E. J. Moon L. D. Popat R. J. King V. R. Bennett G. S. Patel P. N. (2002 ). Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416 636–640.

    Not in our library10.1038/416636a

  21. 21.

    Brauer K. Brückner G. Leibnitz L. Werner L. (1984 ). Structural and cytochemical features of perineuronal glial nets in the rat brain. Acta Histochem. 74 53–60.

    Not in our library10.1016/s0065-1281(84)80026-4

  22. 22.

    Brauer K. Werner L. Leibnitz L. (1982 ). Perineuronal nets of glia. J. Brain Res. 23 701–708.

    Not in our library

  23. 23.

    Brew K. Nagase H. (2010 ). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 1803 55–71.

    Not in our library10.1016/j.bbamcr.2010.01.003

  24. 24.

    Brewton D. H. Kokash J. Jimenez O. Pena E. R. Razak K. A. (2016 ). Age-related deterioration of perineuronal nets in the primary auditory cortex of mice. Front. Aging Neurosci. 8:270.

    Not in our library10.3389/fnagi.2016.00270

  25. 25.

    Brückner G. Brauer K. Härtig W. Wolff J. R. Rickmann M. J. Derouiche A. (1993 ). Perineuronal nets provide a polyanionic, glia-associated form of microenviornment around certain neurons in many parts of the rat brain. Glia 8 183–200.

    Not in our library10.1002/glia.440080306

  26. 26.

    Brückner G. Grosche J. Schmidt S. Härtig W. Margolis R. U. Delpech B. (2000 ). Postnatal development of perineuronal nets in wild type mice and in a mutant deficient in tenascin R. J. Comp. Neurol. 428 616–629.

    Not in our library10.1002/1096-9861(20001225)428:4<616::aid-cne3>3.0.co;2-k

  27. 27.

    Brückner G. Hausen D. Härtig W. Drlicek M. Arendt T. Brauer K. (1999 ). Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer’s disease. Neuroscience 92 719–805.

    Not in our library10.1016/s0306-4522(99)00071-8

  28. 28.

    Bruno M. A. Cuello A. C. (2006 ). Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. U.S.A. 103 6735–6740.

    Not in our library10.1073/pnas.0510645103

  29. 29.

    Cabungcal J. H. Counotte D. S. Lewis E. Tejeda H. A. Piantadosi P. Pollock C. (2014 ). Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 83 1073–1084.

    Not in our library10.1016/j.neuron.2014.07.028

  30. 30.

    Cabungcal J. H. Steullet P. Morishita H. Kraftsik R. Cuenod M. Hensch T. K. (2013 ). Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 110 9130–9135.

    Not in our library10.1073/pnas.1300454110

  31. 31.

    Cañas N. Valero T. Villarroya M. Montell E. Vergés J. García A. G. (2007 ). Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/AKT. J. Pharmacol. Exp. Ther. 323 946–953.

    Not in our library10.1124/jpet.107.123505

  32. 32.

    Cardin J. A. Carlén M. Meletis K. Knoblich U. Zhang F. Deisseroth K. (2009 ). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459 663–667.

    Not in our library10.1038/nature08002

  33. 33.

    Carmichael S. T. Archibeque I. Luke L. Nolan T. Momiy J. Li S. (2005 ). Growth-associated gene expression after stroke: evidence for a growth-promoting region in peri-infarct cortex. Exp. Neurol. 193 291–311.

    Not in our library10.1016/j.expneurol.2005.01.004

  34. 34.

    Caspary D. M. Raza A. Lawhorn Armour B. A. Pippin J. Arneriæ S. P. (1990 ). Immunocytochemical and neurochemical evidence for age-related loss of GABA in the inferior colliculus: implications for neural presbycusis. J. Neurosci. 10 2363–2372.

    Not in our library10.1523/jneurosci.10-07-02363.1990

  35. 35.

    Castrén M. Pääkkönen A. Tarkka I. M. Ryynänen M. Partanen J. (2003 ). Augmentation of auditory N1 in children with fragile X syndrome. Brain Topogr. 15 165–171.

    Not in our library10.1023/a:1022606200636

  36. 36.

    Celio M. R. Blümcke I. (1994 ). Perineuronal nets—a specialized form of extracellular matrix in the adult nervous system. Brain Res. Brain Res. Rev. 19 128–145.

    Not in our library10.1016/0165-0173(94)90006-x

  37. 37.

    Celio M. R. Spreafico R. De Biasi S. Vitellaro-Zuccarello L. (1998 ). Perineuronal nets: past and present. Trends Neurosci. 21 510–515.

    Not in our library10.1016/s0166-2236(98)01298-3

  38. 38.

    Chang M. C. Park J. M. Pelkey K. A. Grabenstatter H. L. Xu D. Linden D. J. (2011 ). Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. Nature 13 1090–1097.

    Not in our library10.1038/nn.2621

  39. 39.

    Chaturvedi M. Kaczmarek L. (2014 ). MMP-9 inhibition: a therapeutic strategy in ischemic stroke. Mol. Neurobiol. 49 563–573.

    Not in our library10.1007/s12035-013-8538-z

  40. 40.
    Modulation of Matrix Metalloproteinases Activity in the Ventral Horn of the Spinal Cord Re-stores Neuroglial Synaptic Homeostasis and Neurotrophic Support following Peripheral Nerve Injury. · 2016
    Not checked
  41. 41.

    Cirillo G. Di Pino G. Capone F. Ranieri F. Florio L. Todisco V. (2017 ). Neurobiological after-effects of non-invasive brain stimulation. Brain Stimul. 10 1–18.

    Not in our library10.1016/j.brs.2016.11.009

  42. 42.

    Claes L. Del-Favero J. Ceulemans B. Lagae L. Van Broeckhoven C. De Jonghe P. (2001 ). De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 68 1327–1332.

    Not in our library10.1086/320609

  43. 43.

    Curley A. A. Arion D. Volk D. W. Asafu-Adjei J. K. Sampson A. R. Fish K. N. (2011 ). Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 168 921–929.

    Not in our library10.1176/appi.ajp.2011.11010052

  44. 44.

    Dansie L. E. Phommahaxay K. Okusanya A. G. Uwadia J. Huang M. Rotschafer S. E. (2013 ). Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. Neuroscience 246 186–198.

    Not in our library10.1016/j.neuroscience.2013.04.058

  45. 45.

    Davies S. J. Goucher D. R. Doller C. Silver J. (1999 ). Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J. Neurosci. 19 5810–5822.

    Not in our library10.1523/jneurosci.19-14-05810.1999

  46. 46.

    Day J. M. Olin A. I. Murdoch A. D. Canfield A. Sasaki T. Timpl R. (2004 ). Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J. Biol. Chem. 279 12511–12518.

    Not in our library10.1074/jbc.m400242200

  47. 47.

    De Felice F. Velasco P. T. Lambert M. P. Viola K. Fernandez S. J. Ferreira S. T. (2007 ). Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282 11590–11601.

    Not in our library10.1074/jbc.m607483200

  48. 48.

    De Luca C. Papa M. (2016 ). Looking inside the matrix: perineuronal nets in plasticity, maladaptive plasticity and neurological disorders. Neurochem. Res. 41 1507–1515.

    Not in our library10.1007/s11064-016-1876-2

  49. 49.

    De Luca C. Savarese L. Colangelo A. M. Bianco M. R. Cirillo G. Alberghina L. (2016 ). Astrocytes and microglia-mediated immune response in maladaptive plasticity is differently modulated by NGF in the ventral horn of the spinal cord following peripheral nerve injury. Cell. Mol. Neurobiol. 36 37–46.

    Not in our library10.1007/s10571-015-0218-2

  50. 50.

    Deibel M. A. Ehmann W. D. Markesbery W. R. (1996 ). Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J. Neurol. Sci. 143 137–142.

    Not in our library10.1016/s0022-510x(96)00203-1

  51. 51.

    Delpech A. Delpech B. (1984 ). Expression of hyaluronic acid-binding glycoprotein, hyaluronectin, in the developing rat embryo. Dev. Biol. 101 391–400.

    Not in our library10.1016/0012-1606(84)90153-2

  52. 52.

    Dityatev A. Brückner G. Dityateva G. Grosche J. Kleene R. Schachner M. (2007 ). Activity-dependent formation and functions of chondroitin sulfate rich extracellular matrix of perineuronal nets. Dev. Biol. 67 570–588.

    Not in our library10.1002/dneu.20361

  53. 53.

    Dityatev A. Rusakov D. (2011 ). Molecular signals of plasticity at the tetrapartite synapse. Curr. Opin. Neurobiol. 21 353–359.

    Not in our library10.1016/j.conb.2010.12.006

  54. 54.

    Do K. Q. Trabesinger A. H. Kirsten-Krüger M. Lauer C. J. Dydak U. Hell D. (2000 ). Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 12 3721–3728.

    Not in our library10.1046/j.1460-9568.2000.00229.x

  55. 55.

    Dziembowska M. Pretto D. I. Janusz A. Kaczmarek L. Leigh M. J. Gabriel N. (2013 ). High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A 161 1897–1903.

    Not in our library10.1002/ajmg.a.36023

  56. 56.

    Enwright J. F. Sanapala S. Foglio A. Berry R. Fish K. N. Lewis D. A. (2016 ). Reduced labeling of parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia. Neuropyschopharmacology 41 2206–2214.

    Not in our library10.1038/npp.2016.24

  57. 57.
    Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome · 2016
    No notice
  58. 58.

    Favuzzi E. Marques-Smith A. Deogracias R. Winterflood C. M. Sánchez-Aguilera A. Mantoan L. (2017 ). Activity-dependent gating of parvalbumin interneuron function by the perineuronal net protein brevican. Neuron 95 639–655.

    Not in our library10.1016/j.neuron.2017.06.028

  59. 59.

    Ferrer I. Oliver B. Russi A. Casas R. Rivera R. (1994 ). Parvalbumin and calbindin-D28k immunocytochemistry in human neocortical epileptic foci. J. Neurol. Sci. 123 18–25.

    Not in our library10.1016/0022-510x(94)90198-8

  60. 60.

    Flatow J. Buckley P. Miller B. J. (2013 ). Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 74 400–409.

    Not in our library10.1016/j.biopsych.2013.03.018

  61. 61.

    Frankland P. W. Wang Y. Rosner B. Shimizu T. Balleine B. W. Dykens E. M. (2004 ). Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol. Psychiatry 9 417–425.

    Not in our library10.1038/sj.mp.4001432

  62. 62.

    Fraser J. R. Laurent T. C. Laurent U. B. (1997 ). Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242 27–33.

    Not in our library10.1046/j.1365-2796.1997.00170.x

  63. 63.

    Frischknecht R. Seidenbecher C. (2008 ). The crosstalk of hyaluronan-based extracellular matrix and synapses. Neuron Glia Biol. 4 249–257.

    Not in our library10.1017/s1740925x09990226

  64. 64.

    Fujiwara T. Sugawara T. Mazaki-Miyazaki E. Takahashi Y. Fukushima K. Watanabe M. (2003 ). Mutations of sodium channel α subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic–clonic seizures. Brain 126 531–546.

    Not in our library10.1093/brain/awg053

  65. 65.

    Galtrey C. M. Kwok J. C. Carulli D. Rhodes K. E. Fawcett J. W. (2008 ). Distribution and synthesis of extracellular matrix proteoglycans, hyaluronan, link proteins and tenascin-R in the rat spinal cord. Eur. J. Neurosci. 27 1373–1390.

    Not in our library10.1111/j.1460-9568.2008.06108.x

  66. 66.

    Gandal M. J. Edgar J. C. Klook K. Siegel S. J. (2012 ). Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology 62 1504–1518.

    Not in our library10.1016/j.neuropharm.2011.02.007

  67. 67.

    Gao F. Wang G. Ma W. Ren F. Li M. Dong Y. (2015 ). Decreased auditory GABA + concentrations in presbycusis demonstrated by edited magnetic resonance. Neuroimage 106 311–316.

    Not in our library10.1016/j.neuroimage.2014.11.023

  68. 68.

    Gary S. C. Zerillo C. A. Chiang V. L. Gaw J. U. Gray G. Hockfield S. (2000 ). cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 256 139–147.

    Not in our library10.1016/s0378-1119(00)00362-0

  69. 69.

    Gates G. Mills J. (2005 ). Presbycusis. Lancet 366 1111–1120.

    Not in our library10.1016/s0140-6736(05)67423-5

  70. 70.

    Giamanco K. A. Morawski M. Matthews R. T. (2010 ). Perineuronal net formation and structure in aggrecan knockout mice. Neuroscience 170 1314–1327.

    Not in our library10.1016/j.neuroscience.2010.08.032

  71. 71.

    Gibson J. R. Bartley A. F. Hays S. A. Huber K. M. (2008 ). Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J. Neurophysiol. 100 2615–2626.

    Not in our library10.1152/jn.90752.2008

  72. 72.

    Glausier J. R. Fish K. N. Lewis D. A. (2014 ). Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. Mol. Psychiatry 19 30–36.

    Not in our library10.1038/mp.2013.152

  73. 73.

    Golgi C. (1893 ). Intorno all’origine del quarto nervo cerebrale e una questione istofisiologica che a questo argomento si collega. Rend. R Accademia Lincei 2 378–389.

    Not in our library

  74. 74.

    Gomis-Rüth F. X. Maskos K. Betz M. Bergner A. Huber R. Suzuki K. (1997 ). Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389 77–81.

    Not in our library10.1038/37995

  75. 75.

    Gu Y. Huang S. Chang M. C. Worley P. Kirkwood A. Quinlan E. M. (2013 ). Obligatory role for the immediate early gene NARP in critical period plasticity. Neuron 79 335–346.

    Not in our library10.1016/j.neuron.2013.05.016

  76. 76.

    Hansson J. Vasan R. S. Ärnlöv J. Ingelsson E. Lind L. Larsson A. (2011 ). Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One 6:e16185.

    Not in our library10.1371/journal.pone.0016185

  77. 77.

    Harris N. G. Mironova Y. A. Hovda D. A. Sutton R. L. (2010 ). Pericontusion axon sprouting is spatially and temporally consistent with a growth-permissive environment after traumatic brain injury. J. Neuropathol. Exp. Neurol. 69 139–154.

    Not in our library10.1097/nen.0b013e3181cb5bee

  78. 78.

    Härtig W. Appel S. Suttkus A. Grosche J. Michalski D. (2016 ). Abolished perineuronal nets and altered parvalbumin-immunoreactivity in the nucleus reticularis thalami of wildtype and 3xTg mice after experimental stroke. Neuroscience 337 66–87.

    Not in our library10.1016/j.neuroscience.2016.09.004

  79. 79.

    Härtig W. Brauer K. Brückner G. (1992 ). Wisteria floribunda agglutinin-labelled nets surround parvalbumin-containing neurons. Neuroreport 3 869–872.

    Not in our library10.1097/00001756-199210000-00012

  80. 80.

    Härtig W. Derouiche A. Welt K. Brauer K. Grosche J. Mäder M. (1999 ). Cortical neurons immunoreactive for the potassium channel Kv3.1b subunit are predominantly surrounded by perineuronal nets presumed as a buffering system for cations. Brain Res. 842 15–29.

    Not in our library10.1016/s0006-8993(99)01784-9

  81. 81.

    Härtig W. Mages B. Aleithe S. Nitzsche B. Altmann S. Barthel H. (2017 ). Damaged neocortical perineuronal nets due to experimental focal cerebral ischemia in mice. rats and sheep. Front. Intergr. Neurosci. 11:15.

    Not in our library10.3389/fnint.2017.00015

  82. 82.

    Hasenstaub A. Otte S. Callaway E. Sejnowski T. J. (2010 ). Metabolic cost as a unifying principle governing neuronal biophysics. Proc. Natl. Acad. Sci. U.S.A. 107 12329–12334.

    Not in our library10.1073/pnas.0914886107

  83. 83.

    Hashimoto T. Arion D. Unger T. Maldonado-Avilés J. G. Morris H. M. Volk D. W. (2008a ). Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 13 147–161.

    Not in our library10.1038/sj.mp.4002011

  84. 84.

    Hashimoto T. Bazmi H. H. Mirnics K. Wu Q. Sampson A. R. Lewis D. A. (2008b ). Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am. J. Psychiatry 165 479–489.

    Not in our library10.1176/appi.ajp.2007.07081223

  85. 85.

    Hashimoto T. Volk D. W. Eggan S. M. Mirnics K. Pierri J. N. Sun Z. (2003 ). Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23 6315–6326.

    Not in our library10.1523/jneurosci.23-15-06315.2003

  86. 86.

    Hauser W. A. (1992 ). The natural history of drug resistant epilepsy: epidemiologic considerations. Epilepsy Res. Suppl. 5 25–28.

    Not in our library

  87. 87.

    Hedrich U. B. Liautard C. Kirschenbaum D. Pofahl M. Lavigne J. Liu Y. (2014 ). Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human NaV1.1 mutation. J. Neurosci. 34 14874–14889.

    Not in our library10.1523/jneurosci.0721-14.2014

  88. 88.

    Hensch T. (2005 ). Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci. 6 877–888.

    Not in our library10.1038/nrn1787

  89. 89.

    Hobohm C. Günther A. Grosche J. Rossner S. Schneider D. Brückner G. (2005 ). Decomposition and long-lasting downregulation of extracellular matrix in perineuronal nets induced by focal cerebral ischemia in rats. J. Neurosci. Res. 80 539–548.

    Not in our library10.1002/jnr.20459

  90. 90.

    Hoover B. R. Reed M. N. Su J. Penrod R. D. Kotilinek L. A. Grant M. K. (2010 ). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68 1067–1081.

    Not in our library10.1016/j.neuron.2010.11.030

  91. 91.

    Inan M. Zhao M. Manuszak M. Karakaya C. Rajadhyaksha A. M. Pickel V. M. (2016 ). Energy deficit in parvalbumin neurons leads to circuit dysfunction, impaired sensory gating and social disability. Neurobiol. Dis. 93 35–46.

    Not in our library10.1016/j.nbd.2016.04.004

  92. 92.

    Irvine S. F. Kwok J. C. (2018 ). Perineuronal nets in spinal motoneurones: chondroitin sulphate proteoglycan around alpha motoneurones. Int. J. Mol. Sci. 19:1172.

    Not in our library10.3390/ijms19041172

  93. 93.

    Janusz A. Milek J. Perycz M. Pacini L. Bagni C. Kaczmarek L. (2013 ). The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J. Neurosci. 33 18234–18241.

    Not in our library10.1523/jneurosci.2207-13.2013

  94. 94.

    Kaas J. H. Qi H. X. Burish M. J. Gharbawie O. A. Onifer S. M. Massey J. M. (2008 ). Cortical and subcortical plasticity in the brains of humans, primates, and rats after damage to sensory afferents in the dorsal columns of the spinal cord. Exp. Neurol. 209 407–416.

    Not in our library10.1016/j.expneurol.2007.06.014

  95. 95.

    Kann O. Papageorgiou I. E. Draguhn A. (2014 ). Highly energized inhibitory interneurons are a central element for information processing in cortical networks. J. Cereb. Blood Flow Metab. 34 1270–1282.

    Not in our library10.1038/jcbfm.2014.104

  96. 96.

    Karetko M. Skangiel-Kramska J. (2009 ). Diverse functions of perineuronal nets. Acta Neurobiol. Exp. 69 564–577.

    Not in our library10.55782/ane-2009-1766

  97. 97.

    Karetko-Sysa M. Skangiel-Kramska J. Nowicka D. (2014 ). Aging somatosensory cortex displays increased density of WFA-binding perineuronal nets associated with GAD-negative neurons. Neuroscience 277 734–746.

    Not in our library10.1016/j.neuroscience.2014.07.049

  98. 98.

    Khodaie-Ardakani M. R. Mirshafiee O. Farokhnia M. Tajdini M. Hosseini S. M. Modabbernia A. (2014 ). Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 215 540–546.

    Not in our library10.1016/j.psychres.2013.12.051

  99. 99.

    Kim G. W. Kim H. J. Cho K. J. Kim H. W. Cho Y. J. Lee B. I. (2009 ). The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol. Dis. 36 169–180.

    Not in our library10.1016/j.nbd.2009.07.008

  100. 100.

    Kim S. Y. Porter B. E. Friedman A. Kaufer D. (2016 ). A potential role for glia-derived extracellular matrix remodeling in postinjury epilepsy. J. Neurosci. Res. 94 794–803.

    Not in our library10.1002/jnr.23758

  101. 101.

    Köppe G. Brückner G. Brauer K. Härtig W. Bigl V. (1997 ). Developmental patterns of proteoglycan-containing extracellular matrix in perineuronal nets and neuropil of the postnatal rat brain. Cell Tissue Res. 288 33–41.

    Not in our library10.1007/s004410050790

  102. 102.

    Kosaka T. Heizmann C. W. (1989 ). Selective staining of a population of parvalbumin-containing GABAergic neurons in the rat cerebral cortex by lectins with specific affinity for terminal N-acetylgalactosamine. Brain Res. 483 158–163.

    Not in our library10.1016/0006-8993(89)90048-6

  103. 103.

    Kwok J. C. Dick G. Wang D. Fawcett J. W. (2011 ). Extracellular matrix and perineuronal nets in CNS repair. Dev. Neurobiol. 71 1073–1089.

    Not in our library10.1002/dneu.20974

  104. 104.

    Kwon J. S. O’Donnell B. F. Wallenstein G. V. Greene R. W. Hirayasu Y. Nestor P. G. (1999 ). Gamma frequency–range abnormalities to auditory stimulation in schizophrenia. Arch. Gen. Psychiatry 56 1001–1005.

    Not in our library10.1001/archpsyc.56.11.1001

  105. 105.

    Lazarus M. Huang Z. (2011 ). Distinct maturation profiles of perisomatic and dendritic targeting GABAergic interneurons in the mouse primary visual cortex during the critical period of ocular dominance plasticity. J. Neurophysiol. 106 775–787.

    Not in our library10.1152/jn.00729.2010

  106. 106.

    Lee C. Yao J. S. Huang Y. Zhai W. Liu W. Guglielmo B. J. (2006 ). Dose–response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J. Cereb. Blood Flow Metab. 26 1157–1164.

    Not in our library10.1038/sj.jcbfm.9600268

  107. 107.

    Leigh M. J. Nguyen D. V. Mu Y. Winarni T. I. Schneider A. Chechi T. (2013 ). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with Fragile X Syndrome. J. Dev. Behav. Pediatr. 34 147–155.

    Not in our library10.1097/dbp.0b013e318287cd17

  108. 108.

    Lemarchant S. Pruvost M. Montaner J. Emery E. Vivien D. Kanninen K. (2013 ). ADAMTS proteoglycanases in the physiological and pathological central nervous system. J. Neuroinflammation 10:133.

    Not in our library10.1186/1742-2094-10-133

  109. 109.

    Lendvai D. Morawski M. Négyessy L. Gáti G. Jäger C. Baksa G. (2013 ). Neurochemical mapping of the human hippocampus reveals perisynaptic matrix around functional synapses in Alzheimer’s disease. Acta Neuropathol. 125 215–229.

    Not in our library10.1007/s00401-012-1042-0

  110. 110.

    Lensjø K. K. Lepperød M. E. Dick G. Hafting T. Fyhn M. (2017 ). Removal of perineuronal nets unlocks juvenile plasticity through network mechanisms of decreased inhibition and increased gamma activity. J. Neurosci. 37 1269–1283.

    Not in our library10.1523/jneurosci.2504-16.2016

  111. 111.

    Lepeta K. Purzycka K. J. Pachulska-Wieczorek K. Mitjans M. Begemann M. Vafadari B. (2017 ). A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Mol. Med. 9 1100–1116.

    Not in our library10.15252/emmm.201707723

  112. 112.

    Levkovitz Y. Mendlovich S. Riwkes S. Braw Y. Levkovitch-Verbin H. Gal G. (2010 ). A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71 138–149.

    Not in our library10.4088/jcp.08m04666yel

  113. 113.

    Light G. A. Hsu J. L. Hsieh M. H. Meyer-Gomes K. Sprock J. Swerdlow N. R. (2006 ). Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol. Psychiatry 60 1231–1240.

    Not in our library10.1016/j.biopsych.2006.03.055

  114. 114.
    Perineuronal nets increase inhibitory GABAergic currents during the critical period in rats · 2013
    Not checked
  115. 115.

    Liu J. Wang Y. Akamatsu Y. Lee C. C. Stetler R. A. Lawton M. T. (2014 ). Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog. Neurobiol. 115 138–156.

    Not in our library10.1016/j.pneurobio.2013.11.004

  116. 116.

    Lorenzl S. Albers D. S. Relkin N. Ngyuen T. Hilgenberg S. L. Chirichigno J. (2003 ). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease. Neurochem. Int. 43 191–196.

    Not in our library10.1016/s0197-0186(03)00004-4

  117. 117.

    Lovelace J. W. Ethell I. M. Binder D. K. Razak K. A. (2018 ). Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome. Neurobiol. Dis. 115 39–48.

    Not in our library10.1016/j.nbd.2018.03.012

  118. 118.

    Lovelace J. W. Wen T. H. Reinhard S. Hsu M. S. Sidhu H. Ethell I. M. (2016 ). Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of fragile X syndrome. Neurobiol. Dis. 89 126–135.

    Not in our library10.1016/j.nbd.2016.02.002

  119. 119.

    Madinier A. Quattromani M. J. Sjölund C. Ruscher K. Wieloch T. (2014 ). Enriched housing enhances recovery of limb placement ability and reduces aggrecan-containing perineuronal nets in the rat somatosensory cortex after experimental stroke. PLoS One 9:e93121.

    Not in our library10.1371/journal.pone.0093121

  120. 120.

    Madsen S. H. Sumer E. U. Bay-Jensen A. C. Sondergaard B. C. Qvist P. Karsdal M. A. (2010 ). Aggrecanase-and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo. Biomarkers 15 266–276.

    Not in our library10.3109/13547500903521810

  121. 121.

    Manczak M. Anekonda T. S. Henson E. Park B. S. Quinn J. Reddy P. H. (2006 ). Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15 1437–1449.

    Not in our library10.1093/hmg/ddl066

  122. 122.

    Martin del Campo H. N. Measor K. R. Razak K. A. (2012 ). Parvalbumin immunoreactivity in the auditory cortex of a mouse model of presbycusis. Hear. Res. 294 31–39.

    Not in our library10.1016/j.heares.2012.08.017

  123. 123.

    Massey J. M. Amps J. Viapiano M. S. Matthews R. T. Wagoner M. R. Whitaker C. M. (2008 ). Increased chondroitin sulfate proteoglycan expression in denervated brainstem targets following spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase ABC and neurotrophin-3. Exp. Neurol. 209 426–445.

    Not in our library10.1016/j.expneurol.2007.03.029

  124. 124.

    Massey J. M. Hubscher C. H. Wagoner M. R. Decker J. A. Amps J. Silver J. (2006 ). Chondroitinase ABC digestion of the perineuronal net promotes functional collateral sprouting in the cuneate nucleus after cervical spinal cord injury. J. Neurosci. 26 4406–4414.

    Not in our library10.1523/jneurosci.5467-05.2006

  125. 125.

    Matthews R. T. Kelly G. M. Zerillo C. A. Gray G. Tiemeyer M. Hockfield S. (2002 ). Aggrecan glycoforms contribute to the molecular heterogeneity of perineuronal nets. J. Neurosci. 22 7536–7547.

    Not in our library10.1523/jneurosci.22-17-07536.2002

  126. 126.

    Mauney S. A. Athanas K. M. Pantazopoulos H. Shaskan N. Passeri E. Berretta S. (2013 ). Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol. Psychiatry 74 427–435.

    Not in our library10.1016/j.biopsych.2013.05.007

  127. 127.

    McRae P. Porter B. (2012 ). The perineuronal net component of the extracellular matrix in plasticity and epilepsy. Neurochem. Int. 61 963–972.

    Not in our library10.1016/j.neuint.2012.08.007

  128. 128.

    Mellios N. Huang H. S. Baker S. P. Galdzicka M. Ginns E. Akbarian S. (2009 ). Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 65 1006–1014.

    Not in our library10.1016/j.biopsych.2008.11.019

  129. 129.

    Mercuri F. A. Maciewicz R. A. Tart J. Last K. Fosang A. J. (2000 ). Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J. Biol. Chem. 275 33038–33045.

    Not in our library10.1074/jbc.275.42.33038

  130. 130.

    Meyer-Puttlitz B. Junker E. Margolis R. U. Margolis R. K. (1996 ). Chondroitin sulfate proteoglycans in the developing central nervous system. II. Immunocytochemical localization of neurocan and phosphacan. J. Comp. Neurol. 366 44–54.

    Not in our library10.1002/(sici)1096-9861(19960226)366:1<44::aid-cne4>3.0.co;2-k

  131. 131.

    Milev P. Maurel P. Chiba A. Mevissen M. Popp S. Yamaguchi Y. (1998 ). Differential regulation of expression of hyaluronan-binding proteoglycans in developing brain: aggrecan, versican, neurocan, and brevican. Biochem. Biophys. Res. Commun. 247 207–212.

    Not in our library10.1006/bbrc.1998.8759

  132. 132.

    Miller B. Sheppard A. M. Bicknese A. R. Pearlman A. L. (1996 ). Chondroitin sulphate proteoglycans in the developing cerebral cortex: The distribution of neurocan distinguishes forming afferent and efferent axonal pathways. J. Comp. Neurol. 355 615–628.

    Not in our library10.1002/cne.903550410

  133. 133.

    Miyaoka T. Yasukawa R. Yasuda H. Hayashida M. Inagaki T. Horiguchi J. (2008 ). Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol. 31 287–292.

    Not in our library10.1097/wnf.0b013e3181593d45

  134. 134.

    Miyata S. Nishimura Y. Nakashima T. (2007 ). Perineuronal nets protect against amyloid β-protein neurotoxicity in cultured cortical neurons. Brain Res. 1150 200–206.

    Not in our library10.1016/j.brainres.2007.02.066

  135. 135.

    Moore A. Wehr M. (2012 ). Parvalbumin-expressing inhibitory interneurons in auditory cortex are well-tuned for frequency. J. Neurosci. 33 13713–13723.

    Not in our library10.1523/jneurosci.0663-13.2013

  136. 136.

    Morawski M. Brückner G. Jäger C. Seeger G. Arendt T. (2010 ). Neurons associated with aggrecan-based perineuronal nets are protected against tau pathology in subcortical regions in Alzheimer’s disease. J. Neurosci. 169 1347–1363.

    Not in our library10.1016/j.neuroscience.2010.05.022

  137. 137.

    Morawski M. Brückner M. K. Riederer P. Brückner G. Arendt T. (2004 ). Perineuronal nets potentially protect against oxidative stress. Exp. Neurol. 188 309–315.

    Not in our library10.1016/j.expneurol.2004.04.017

  138. 138.

    Morishita H. Cabungcal J. H. Chen Y. Do K. Q. Hensch T. K. (2015 ). Prolonged period of cortical plasticity upon redox dysregulation in fast-spiking interneurons. Biol. Psychiatry 78 396–402.

    Not in our library10.1016/j.biopsych.2014.12.026

  139. 139.

    Murase S. Lantz C. L. Quinlan E. M. (2017 ). Light reintroduction after dark exposure reactivates plasticity in adults via perisynaptic activation of MMP-9. eLife 6:e27345.

    Not in our library10.7554/elife.27345

  140. 140.

    Murray J. Cuckle H. Taylor G. Hewison J. (1997 ). Screening for fragile X syndrome. Health Technol. Assess. 1 i–iv, 1–71.

    Not in our library

  141. 141.

    Musumeci S. A. Bosco P. Calabrese G. Bakker C. De Sarro G. B. Elia M. (2000 ). Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41 19–23.

    Not in our library10.1111/j.1528-1157.2000.tb01499.x

  142. 142.

    Nakagawa F. Schulte B. A. Wu J. Y. Spicer S. S. (1986 ). GABAergic neurons of rodent brain correspond partially with those staining for glycoconjugate with terminal N-acetylgalactosamine. J. Neurocytol. 15 389–396.

    Not in our library10.1007/bf01611440

  143. 143.

    Nguyen A. Khaleel H. M. Razak K. A. (2017 ). Effects of noise-induced hearing loss on parvalbumin and perineuronal net expression in the mouse primary auditory cortex. Hear. Res. 350 82–90.

    Not in our library10.1016/j.heares.2017.04.015

  144. 144.

    Nomura T. Musial T. F. Marshall J. J. Zhu Y. Remmers C. L. Xu J. (2017 ). Delayed maturation of fast-spiking interneurons is rectified by activation of the TrkB receptor in the mouse model of fragile X syndrome. J. Neurosci. 37 11298–11310.

    Not in our library10.1523/jneurosci.2893-16.2017

  145. 145.

    Nowicka D. Soulsby S. Skangiel-Kramska J. Glazewski S. (2009 ). Parvalbumin-containing neurons, perineuronal nets and experience-dependent plasticity in murine barrel cortex. Eur. J. Neurosci. 30 2053–2063.

    Not in our library10.1111/j.1460-9568.2009.06996.x

  146. 146.

    O’Brien R. J. Xu D. Petralia R. S. Steward O. Huganir R. L. Worley P. (1999 ). Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product narp. Neuron 23 309–323.

    Not in our library10.1016/s0896-6273(00)80782-5

  147. 147.

    Ogiwara I. Miyamoto H. Morita N. Atapour N. Mazaki E. Inoue I. (2007 ). Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 27 5903–5914.

    Not in our library10.1523/jneurosci.5270-06.2007

  148. 148.

    Oohashi T. Edamatsu M. Bekku Y. Carulli D. (2015 ). The hyaluronan and proteoglycan link proteins: organizers of the brain extracellular matrix and key molecules for neuronal function and plasticity. Exp. Neurol. 274 134–144.

    Not in our library10.1016/j.expneurol.2015.09.010

  149. 149.

    Ouda L. Druga R. Syka J. (2008 ). Changes in parvalbumin immunoreactivity with aging in the central auditory system of the rat. Exp. Gerontol. 43 782–789.

    Not in our library10.1016/j.exger.2008.04.001

  150. 150.

    Palop J. J. Chin J. Roberson E. D. Wang J. Thwin M. T. Bien-Ly N. (2007 ). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of alzheimer’s disease. Neuron 55 697–711.

    Not in our library10.1016/j.neuron.2007.07.025

  151. 151.

    Papa M. De Luca C. Petta F. Alberghina L. Cirillo G. (2014 ). Astrocyte–neuron interplay in maladaptive plasticity. Neurosci. Biobehav. Rev. 42 35–54.

    Not in our library10.1016/j.neubiorev.2014.01.010

  152. 152.
    Open-label add-on treatment trial of minocycline in fragile X syndrome · 2010
    No notice
  153. 153.

    Peress N. Perillo E. Zucker S. (1995 ). Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer’s disease and normal brain. J. Neuropathol. Exp. Neurol. 54 16–22.

    Not in our library10.1097/00005072-199501000-00002

  154. 154.

    Pizzo R. Gurgone A. Castroflorio E. Amendola E. Gross C. Sassoè-Pognetto M. (2016 ). Lack of Cdkl5 disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex. Front. Cell. Neurosci. 10:261.

    Not in our library10.3389/fncel.2016.00261

  155. 155.

    Pizzorusso T. Medini P. Berardi N. Chierzi S. Fawcett J. W. Maffei L. (2002 ). Reactivation of ocular dominance plasticity in the adult visual cortex. Science 298 1248–1251.

    Not in our library10.1126/science.1072699

  156. 156.

    Pollock E. Everest M. Brown A. Poulter M. O. (2014 ). Metalloproteinase inhibition prevents inhibitory synapse reorganization and seizure genesis. Neurobiol. Dis. 70 21–31.

    Not in our library10.1016/j.nbd.2014.06.003

  157. 157.

    Popp S. Andersen J. S. Maurel P. Margolis R. U. (2003 ). Localization of aggrecan and versican in the developing rat central nervous system. Dev. Dyn. 227 143–149.

    Not in our library10.1002/dvdy.10282

  158. 158.

    Puel J. L. Ruel J. Gervais d’Aldin C. Pujol R. (1998 ). Excitotoxicity and repair of cochlear synapses after noise-trauma induced hearing loss. Neuroreport 9 2109–2114.

    Not in our library10.1097/00001756-199806220-00037

  159. 159.

    Pyka M. Wetzel C. Aguado A. Geissler M. Hatt H. Faissner A. (2011 ). Chondroitin sulfate proteoglycans regulate astrocyte-dependent synaptogenesis and modulate synaptic activity in primary embryonic hippocampal neurons. Eur. J. Neurosci. 33 2187–2202.

    Not in our library10.1111/j.1460-9568.2011.07690.x

  160. 160.

    Quattromani M. J. Pruvost M. Guerreiro C. Backlund F. Englund E. Aspberg A. (2018 ). Extracellular matrix modulation is driven by experience-dependent plasticity during stroke recovery. Mol. Neurobiol. 55 2196–2213.

    Not in our library10.1007/s12035-017-0461-2

  161. 161.

    Rahimi S. Sayad A. Moslemi E. Ghafouri-Fard S. Taheri M. (2017 ). Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients. Metab. Brain Dis. 32 1537–1542.

    Not in our library10.1007/s11011-017-0043-z

  162. 162.

    Ramón Y. Cajal S. (1897 ). Las células de cilindro-eje corto de la capa molecular del cerebro. Rev. Trim Micrográf. 2 105–127.

    Not in our library

  163. 163.

    Rankin-Gee E. K. McRae P. A. Baranov E. Rogers S. Wandrey L. Porter B. E. (2015 ). Perineuronal net degradation in epilepsy. Epilepsia 56 1124–1133.

    Not in our library10.1111/epi.13026

  164. 164.

    Reinart T. Morawskib T. Arendtb T. Butz T. (2003 ). Quantitative microanalysis of perineuronal nets in brain tissue. Nucl. Instrum. Methods Phys. Res. B 210 395–400.

    Not in our library10.1016/s0168-583x(03)01041-3

  165. 165.
    A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders · 2015
    No notice
  166. 166.

    Roberson E. Halabisky B. Yoo J. W. Yao J. Chin J. Yan F. (2011 ). Amyloid-β/fyn–induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s Disease. J. Neurosci. 31 700–711.

    Not in our library10.1523/jneurosci.4152-10.2011

  167. 167.

    Rogers S. J. Wehner D. E. Hagerman R. (2001 ). The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J. Dev. Behav. Pediatr. 22 409–417.

    Not in our library10.1097/00004703-200112000-00008

  168. 168.

    Rojas D. C. Benkers T. L. Rogers S. J. Teale P. D. Reite M. L. Hagerman R. J. (2001 ). Auditory evoked magnetic fields in adults with fragile X syndrome. Neuroreport 12 2573–2576.

    Not in our library10.1097/00001756-200108080-00056

  169. 169.

    Rotschafer S. Razak K. (2013 ). Altered auditory processing in a mouse model of fragile X syndrome. Brain Res. 1506 12–24.

    Not in our library10.1016/j.brainres.2013.02.038

  170. 170.

    Rotschafer S. Razak K. (2014 ). Auditory processing in fragile X syndrome. Front. Cell. Neurosci. 8:19

    Not in our library10.3389/fncel.2014.00019

  171. 171.

    Rotschafer S. E. Trujillo M. S. Dansie L. E. Ethell I. M. Razak K. A. (2012 ). Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Res. 1439 7–14.

    Not in our library10.1016/j.brainres.2011.12.041

  172. 172.

    Ruiter J. Uyling H. (1987 ). Morphometric and dendritic analysis of fascia dentata granule cells in human again and senile dementia. Brain Res. 402 217–229.

    Not in our library10.1016/0006-8993(87)90028-x

  173. 173.

    Rybakowski J. K. Skibinska M. Kapelski P. Kaczmarek L. Hauser J. (2009 ). Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizohr. Res. 109 90–93.

    Not in our library10.1016/j.schres.2009.02.005

  174. 174.
    Genome-Wide Target Analyses of Otx2 Homeoprotein in Postnatal Cortex · 2017
    Not checked
  175. 175.

    Scheibel A. Tomiyasu U. (1978 ). Dendritic sprouting in alzheimer’s presenile dementia. Exp. Neurol. 60 1–8.

    Not in our library10.1016/0014-4886(78)90164-4

  176. 176.

    Schneider A. Leigh M. J. Adams P. Nanakul R. Chechi T. Olichney J. (2013 ). Electrocortical changes associated with minocycline treatment in fragile X syndrome. J. Psychopharmacol. 27 956–963.

    Not in our library10.1177/0269881113494105

  177. 177.

    Schwaller B. Tetko I. V. Tandon P. Silveira D. C. Vreugdenhil M. Henzi T. (2004 ). Parvalbumin deficiency affects network properties resulting in increased susceptibility to epileptic seizures. Mol. Cell. Neurosci. 25 650–663.

    Not in our library10.1016/j.mcn.2003.12.006

  178. 178.

    Sheppard A. M. Hamilton S. K. Pearlman A. L. (1991 ). Changes in the distribution of extracellular matrix components accompany early morphogenetic events of mammalian cortical development. J. Neurosci. 11 3928–3942.

    Not in our library10.1523/jneurosci.11-12-03928.1991

  179. 179.

    Sherman L. Back S. (2007 ). A ‘GAG’ reflex prevents repair of the damage CNS. Trends Neurosci. 31 44–52.

    Not in our library10.1016/j.tins.2007.11.001

  180. 180.

    Sinclair D. Featherstone R. Naschek M. Nam J. Du A. Wright S. (2017a ). GABA-B agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of Fragile X Syndrome. eNeuro 4 ENEURO.0380-16.2017.

    Not in our library10.1523/eneuro.0380-16.2017

  181. 181.

    Sinclair D. Oranje B. Razak K. A. Siegel S. J. Schmid S. (2017b ). Sensory processing in autism spectrum disorders and Fragile X syndrome—From the clinic to animal models. Neurosci. Biobehav. Rev. 76 235–253.

    Not in our library10.1016/j.neubiorev.2016.05.029

  182. 182.

    Sloviter R. S. Sollas A. L. Barbaro N. M. Laxer K. D. (1991 ). Calcium-binding protein (calbindin-D28K) and parvalbumin immunocytochemistry in the normal and epileptic human hippocampus. J. Comp. Neurol. 308 381–396.

    Not in our library10.1002/cne.903080306

  183. 183.

    Smith A. C. Scofield M. D. Kalivas P. W. (2015 ). The tetrapartite synapse: extracellular matrix remodeling contributes to corticoaccumbens plasticity underlying drug addiction. Brain Res. 1628 29–39.

    Not in our library10.1016/j.brainres.2015.03.027

  184. 184.

    Sohal V. S. Zhang F. Yizhar O. Deisseroth K. (2009 ). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459 698–702.

    Not in our library10.1038/nature07991

  185. 185.

    Sorg B. A. Berretta S. Blacktop J. M. Fawcett J. W. Kitagawa H. Kwok J. C. (2016 ). Casting a wide net: role of perineuronal nets in neural plasticity. J. Neurosci. 36 11459–11468.

    Not in our library10.1523/jneurosci.2351-16.2016

  186. 186.

    Steullet P. Cabungcal J. H. Cuénod M. Do K. Q. (2014 ). Fast oscillatory activity in the anterior cingulate cortex: dopaminergic modulation and effect of perineuronal net loss. Front. Cell. Neurosci. 8:244.

    Not in our library10.3389/fncel.2014.00244

  187. 187.

    Stohs W. Bagchi D. (1995 ). Oxidative mechanisms in the toxicity of metal ions. Free Radic. Biol. Med. 18 321–336.

    Not in our library10.1016/0891-5849(94)00159-h

  188. 188.

    Sugiyama S. Di Nardo A. A. Aizawa S. Matsuo I. Volovitch M. Prochiantz A. (2008 ). Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity. Cell 134 508–520.

    Not in our library10.1016/j.cell.2008.05.054

  189. 189.

    Sun B. Halabisky B. Zhou Y. Palop J. J. Yu G. Mucke L. (2009 ). Imbalance between GABAergic and glutamatergic transmission impairs adult neurogenesis in an animal model of Alzheimer’s Disease. Cell Stem Cell 5 624–633.

    Not in our library10.1016/j.stem.2009.10.003

  190. 190.

    Suttkus A. Rohn S. Jäger C. Arendt T. Morawski M. (2012 ). Neuroprotection against iron-induced cell death by perineuronal nets - an in vivo analysis of oxidative stress. Am. J. Neurodegener. Dis. 1 122–129.

    Not in our library

  191. 191.

    Suttkus A. Rohn S. Weigel S. Glöckner P. Arendt T. Morawski M. (2014 ). Aggrecan, link protein and tenascin-R are essential components of the perineuronal net to protect neurons against iron-induced oxidative stress. Cell Death Dis. 5:e1119.

    Not in our library10.1038/cddis.2014.25

  192. 192.

    Syka J. (2002 ). Plastic changes in the central auditory system after hearing loss, restoration of function, and during learning. Physiol. Rev. 82 601–636.

    Not in our library10.1152/physrev.00002.2002

  193. 193.

    Tosic M. Ott J. Barral S. Bovet P. Deppen P. Gheorghita F. (2006 ). Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 79 586–592.

    Not in our library10.1086/507566

  194. 194.

    Trujillo M. Razak K. (2013 ). Altered cortical spectrotemporal processing with age-related hearing loss. J. Neurophysiol. 110 2873–2886.

    Not in our library10.1152/jn.00423.2013

  195. 195.

    Ueno H. Suemitsu S. Okamoto M. Matsumoto Y. Ishihara T. (2017a ). Parvalbumin neurons and perineuronal nets in the mouse prefrontal cortex. Neuroscience 343 115–127.

    Not in our library10.1016/j.neuroscience.2016.11.035

  196. 196.

    Ueno H. Suemitsu S. Okamoto M. Matsumoto Y. Ishihara T. (2017b ). Sensory experience-dependent formation of perineuronal nets and expression of Cat-315 immunoreactive components in the mouse somatosensory cortex. Neuroscience 355 161–174.

    Not in our library10.1016/j.neuroscience.2017.04.041

  197. 197.

    Ueno H. Takao K. Suemitsu S. Murakami S. Kitamura N. Wani K. (2017c ). Age-dependent and region-specific alteration of parvalbumin neurons and perineuronal nets in the mouse cerebral cortex. Neurochem. Int. 112 59–70.

    Not in our library10.1016/j.neuint.2017.11.001

  198. 198.

    Uhlhaas P. J. Roux F. Singer W. Haenschel C. Sireteanu R. Rodriguez E. (2009 ). The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. Proc. Natl. Acad. Sci. U.S.A. 106 9866–9871.

    Not in our library10.1073/pnas.0900390106

  199. 199.

    Van der Molen M. J. Van der Molen M. W. Ridderinkhof K. R. Hamel B. C. Curfs L. M. Ramakers G. J. (2012 ). Auditory and visual cortical activity during selective attention in fragile X syndrome: a cascade of processing deficiencies. Clin. Neurophysiol. 123 720–729.

    Not in our library10.1016/j.clinph.2011.08.023

  200. 200.

    Varadarajan S. Yatin S. Aksenova M. Butterfield D. A. (2000 ). Alzheimer’s amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130 184–208.

    Not in our library10.1006/jsbi.2000.4274

  201. 201.

    Verkerk A. J. Pieretti M. Sutcliffe J. S. Fu Y. H. Kuhl D. P. Pizzuti A. (1991 ). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65 905–914.

    Not in our library10.1016/0092-8674(91)90397-h

  202. 202.

    Volk D. W. Austin M. C. Pierri J. N. Sampson A. R. Lewis D. A. (2000 ). Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57 237–245.

    Not in our library10.1001/archpsyc.57.3.237

  203. 203.

    Wang D. Fawcett J. (2012 ). The perineuronal net and the control of CNS plasticity. Cell Tissue Res. 349 147–160.

    Not in our library10.1007/s00441-012-1375-y

  204. 204.
    A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome · 2017
    No notice
  205. 205.

    Wegner F. Härtig W. Bringmann A. Grosche J. Wohlfarth K. (2003 ). Diffuse perineuronal nets and modified pyramidal cells immunoreactive for glutamate and the GABA A receptor α1 subunit form a unique entity in rat cerebral cortex. Exp. Neurol. 184 705–714.

    Not in our library10.1016/s0014-4886(03)00313-3

  206. 206.

    Wen T. H. Afroz S. Reinhard S. M. Palacios A. R. Tapia K. Binder D. K. (2017 ). Genetic reduction of matrix metalloproteinase-9 promotes formation of perineuronal nets around parvalbumin-expressing interneurons and normalizes auditory cortex responses in developing Fmr1 knock-out mice. Cereb. Cortex 13 1–14.

    Not in our library10.1093/cercor/bhx258

  207. 207.

    Wilczynski G. M. Konopacki F. A. Wilczek E. Lasiecka Z. Gorlewicz A. Michaluk P. (2008 ). Important role of matrix metalloproteinase 9 in epileptogenesis. J. Cell Biol. 180 1021–1035.

    Not in our library10.1083/jcb.200708213

  208. 208.

    Xie Y. Chen S. Wu Y. Murphy T. H. (2014 ). Prolonged deficits in parvalbumin neuron stimulation-evoked network activity despite recovery of dendritic structure and excitability in the somatosensory cortex following global ischemia in mice. J. Neurosci. 34 14890–14900.

    Not in our library10.1523/jneurosci.1775-14.2014

  209. 209.

    Yamada J. Jinno S. (2017 ). Molecular heterogeneity of aggrecan-based perineuronal nets around five subclasses of parvalbumin-expressing neurons in the mouse hippocampus. J. Comp. Neurol. 525 1234–1249.

    Not in our library10.1002/cne.24132

  210. 210.

    Yamaguchi Y. (1999 ). Lecticans: organizers of the brain extracellular matrix. Cell. Mol. Life Sci. 57 276–289.

    Not in our library10.1007/pl00000690

  211. 211.

    Yamamori H. Hashimoto R. Ishima T. Kishi F. Yasuda Y. Ohi K. (2013 ). Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci. Lett. 556 37–41.

    Not in our library10.1016/j.neulet.2013.09.059

  212. 212.
    Altered Glutathione Redox State in Schizophrenia · 2006
    No notice
  213. 213.

    Yutsudo N. Kitagawa H. (2015 ). Involvement of chondroitin 6-sulfation in temporal lobe epilepsy. Exp. Neurol. 274 126–133.

    Not in our library10.1016/j.expneurol.2015.07.009

  214. 214.

    Zhang H. Chang M. Hansen C. N. Basso D. M. Noble-Haeusslein L. J. (2011 ). Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 8 206–220.

    Not in our library10.1007/s13311-011-0038-0

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.